Market Segmentation

• Based on technology, the market is segmented into machine learning, deep learning, natural language processing (NLP), computer vision, and other AI technologies.
• Based on the drug discovery stage, the market is segmented into target identification & validation, hit identification & screening, lead optimization, preclinical testing, clinical trials, and drug repurposing.
• Based on the application, the market is segmented into oncology, neurology, cardiovascular diseases, infectious diseases, metabolic disorders, and others.
• Based on the end user, the market is segmented into pharmaceutical companies, biotechnology companies, contract research organizations (CROs), research institutes, and others.

Target Identification & Validation segment Dominates the Market with the Largest Share

The target identification & validation segment held the highest market share in the global AI in drug discovery market, driven by rapid adoption of AI/ML in genomics, proteomics, and disease pathway mapping. This stage dominates because it delivers the highest efficiency gains in early drug discovery by improving target accuracy and reducing downstream clinical failure rates. According to the National Institutes of Health (NIH), the All of Us Research Program has enrolled over 747,000 participants, generated more than 535,000 whole-genome sequences, and produced over 275 million genetic variants, making it one of the most comprehensive biomedical datasets globally for AI-driven target discovery and validation. The program also integrates millions of electronic health records, enabling large-scale genotype–phenotype analysis for precision drug target identification. In addition, the National Human Genome Research Institute (NHGRI) reports that the cost of sequencing a human genome has dropped from nearly $100 million in 2001 to under USD 1,000 today, enabling massive expansion of genomic datasets used in AI-powered drug discovery pipelines. This dramatic cost reduction has significantly accelerated target identification research across pharmaceutical and biotech companies.

Machine Learning Holds a Significant Market Share

The machine learning segment held the highest market share, making it the dominant technology segment owing  to its wide deployment across virtual screening, molecular simulation, and predictive modeling workflows. The dominance of machine learning is strongly supported by the scale of computational adoption in drug R&D. Industry benchmarks indicate that over 80% of AI-driven drug discovery workflows today involve machine learning models at the screening or prediction stage, compared to less than 20% for alternative AI methods such as computer vision or NLP-based biomedical text mining. In addition, machine learning systems in drug discovery are increasingly trained on datasets containing 10–50 billion molecular interaction records across global bioinformatics databases, enabling large-scale compound prediction and toxicity analysis. Modern ML platforms can evaluate over 1–5 million chemical compounds per screening cycle, significantly accelerating early-stage drug discovery timelines from years to months. Furthermore, cloud-based drug discovery platforms report that ML-based models reduce computational screening costs by 30–60% compared to traditional high-throughput laboratory screening methods, making it the most cost-efficient AI technology in pharmaceutical R&D.

Regional Outlook

The global AI in drug discovery market is segmented geographically into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia & New Zealand, ASEAN Countries, and Rest of Asia-Pacific), and the Rest of the World (Middle East & Africa and Latin America).

Europe’s Strong Research Ecosystem Driving AI in Drug Discovery Growth

Europe AI in Drug Discovery market is supported by strong public funding for life sciences, cross-border research programs, and increasing adoption of AI-driven healthcare innovation. According to the European Commission, Horizon Europe has a total budget of €95.5 billion (2021–2027), with a significant portion allocated to health, biotechnology, AI, and personalized medicine research, supporting advanced drug discovery initiatives across member states. In addition, the European Bioinformatics Institute (EMBL-EBI) maintains some of the global largest biological and genomic databases, containing millions of genomic sequences, protein structures, and multi-omics datasets, which are widely used in AI-based drug discovery, target identification, and molecular modeling. Furthermore, the European Medicines Agency (EMA) is increasingly supporting the use of AI, real-world evidence, and advanced analytics in regulatory science, accelerating the approval and validation of innovative therapeutics. Strong collaboration between leading pharmaceutical companies such as Roche Holding AG, Novartis AG, and AstraZeneca PLC with AI and biotech firms is further driving adoption of AI-powered drug discovery technologies across Europe.

North America Region Dominates the Market with Major Share

North America held the highest market share in the AI in drug discovery market, driven by strong pharmaceutical R&D infrastructure, advanced AI adoption, and significant public-private investments in biomedical innovation. According to the National Institutes of Health, the All of Us Research Program has enrolled more than 747,000 participants and generated over 535,000 whole-genome sequences, making it one of the largest biomedical datasets supporting precision medicine and AI-driven drug discovery research. The program has also identified more than 275 million genetic variants, significantly enhancing target identification and disease modeling capabilities. Furthermore, the U.S. Food and Drug Administration continues to accelerate approvals of AI-enabled diagnostics and companion diagnostic tools, supporting the integration of AI in drug development and personalized therapies. In addition, organizations such as the Advanced Research Projects Agency.

Market Players Outlook

The major companies operating in the global AI in drug discovery market include Alphabet Inc. (Isomorphic Labs), Microsoft Corp., IBM Corp., NVIDIA Corp. and Bristol Myers Squibb Company. Industry players are focusing on partnerships, collaborations, and mergers, and acquisitions activities to broaden their market reach, foster innovation, and reinforce their market standing.

Recent Developments

• In June 2026, SK Biopharmaceuticals and Insilico Medicine signed a strategic AI drug discovery partnership valued at more than $2.5 billion to develop neuroimmune therapies. The collaboration leverages Insilco’s generative AI platform for candidate design, while SK Biopharmaceuticals manages late-stage development and commercialization.

• In June 2026, Incyte Corp. and Genesis Therapeutics expanded their AI drug discovery collaboration with an upfront investment of $120 million, including equity funding and research commitments. The partnership focuses on applying Genesis’ molecular AI platform and Incyte’s proprietary datasets to accelerate small-molecule drug discovery across oncology, hematology, and inflammation targets.

• In June 2026, Sanofi and Owkin entered a multi-year collaboration to develop next-generation AI biopharma agents for end-to-end drug discovery and development. The partnership builds on earlier oncology-focused cooperation and aims to deploy agentic AI systems for target identification, drug positioning, and clinical research optimization.

• In May 2026, Incyte Corp. and Genesis Therapeutics further strengthened their AI-driven drug discovery partnership with expanded funding of $80 million upfront and additional equity investment. The collaboration now covers multiple therapeutic targets and integrates large-scale AI model training using proprietary pharmaceutical datasets.

• In March 2026, Eli Lilly and Company and Insilico Medicine announced an expanded collaboration valued at up to $2.75 billion to accelerate AI-driven drug discovery for oral therapies. The partnership integrates Insilico’s Pharma. AI platform with Lilly’s drug development capabilities to design and advance novel preclinical drug candidates for multiple disease areas.

The Report Covers

• Market valuation analysis for 2026 with projections through 2035.
• Profiles of leading AI in drug discovery companies, covering recent developments and strategic initiatives.
• Segment-wise revenue forecasts and estimates ($ Million).
• Comprehensive country-level insights across key geographic regions.
• Analysis of high-growth segments and future market opportunities.
• Evaluation of market penetration and expansion strategies.
• Competitive landscape assessment and player positioning analysis.

Key Market Players

• AbCellera Biologics Inc.
• Alphabet Inc. (Google DeepMind)
• Amazon Web Services, Inc.
• Arctoris Ltd.
• Atomwise, Inc.
• BenevolentAI Ltd.
• BioAge Labs, Inc.
• Certara, Inc.
• Cyclica Inc.
• Deep Genomics Inc.
• Envisagenics, Inc.
• Evotec SE
• Exscientia plc
• Generate: Biomedicines, Inc.
• Genesis Therapeutics, Inc.
• Healx Limited
• IBM Corp.
• Iktos S.A.
• Immunai, Inc.
• Insilico Medicine
• Insitro, Inc.
• Isomorphic Labs Ltd.
• Lantern Pharma Inc.
• Microsoft Corp.
• NVIDIA Corp.
• Oracle Corp.
• Owkin, Inc.
• PathAI, Inc.
• Peptone Ltd.
• Quris Technologies Ltd.
• Recursion Pharmaceuticals, Inc.
• Relay Therapeutics, Inc.
• Schrödinger, Inc.
• Standigm Inc.
• Tempus AI, Inc.
• Valo Health, Inc.
• Verge Genomics, Inc.
• XtalPi Holdings Ltd.